Latest Australian Securities Exchange News

Truscott Mining has begun its RC drilling program at the Westminster Project, with the ASX confirming no suspension will occur as of mid-February. Investors await assay results expected in the coming months.

Bubalus Resources has responded to ASX concerns over a delayed director interest notice, attributing the lapse to an administrative oversight and reaffirming its commitment to compliance.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payment to Australian CDI holders, impacting the Australian dollar amount payable per share. The dividend remains unfranked and subject to US withholding tax, with a reduced rate available under the US-Australia tax treaty.

Us1 Critical Minerals Limited’s USCO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing and next steps.

Assetora Limited is set to be delisted from the ASX after a two-year suspension, with the company exploring a fresh listing on the National Stock Exchange of Australia to better suit its evolving business model.

Australian Vanadium Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information behind the market activity.

Finder Energy Holdings has clarified that its recent share price jump is driven by investor enthusiasm around key project milestones, dismissing any undisclosed information as a cause.

Titanium Sands Limited has responded to ASX inquiries following a sharp share price drop and increased trading volume, confirming no undisclosed price-sensitive information. The company highlighted an unrelated Sri Lankan Supreme Court petition on illegal mining near its pending Mannar Island project.

Cobre Limited has voluntarily suspended its ASX trading to finalise details of a significant acquisition and placement, with an announcement expected imminently.

EMC Gold has responded to an ASX price query following a sudden spike in its share price, confirming no undisclosed information exists and affirming compliance with continuous disclosure rules.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.